Recent genomic profiling efforts have provided deep understanding of molecular pathogenesis of HCC and a number of overactivated tumor driver pathways have been identified such as the Wnt and mTOR signaling pathways and but only a few are druggable targets by conventional treatment [11–13]. This evidence concerns the gene MTOR and hepatocellular carcinoma.